CO6751248A2 - Compuestos sustituidos de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida como inhibidores de la tirosina quinasa receptora de tipo iii - Google Patents

Compuestos sustituidos de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida como inhibidores de la tirosina quinasa receptora de tipo iii

Info

Publication number
CO6751248A2
CO6751248A2 CO13167580A CO13167580A CO6751248A2 CO 6751248 A2 CO6751248 A2 CO 6751248A2 CO 13167580 A CO13167580 A CO 13167580A CO 13167580 A CO13167580 A CO 13167580A CO 6751248 A2 CO6751248 A2 CO 6751248A2
Authority
CO
Colombia
Prior art keywords
indazol
imidazo
carboxamide
pyridin
tyrosine kinase
Prior art date
Application number
CO13167580A
Other languages
English (en)
Spanish (es)
Inventor
Mark L Boys
Robert Kirk Delisle
Erik James Hicken
April Layne Kennedy
David A Mareska
Fredrik Pehr Marmsater
Mark Munson
Brad Newhouse
Bryson Rast
James P Rizzi
Martha E Rodriguez
George T Topalov
Qian Zhao
Original Assignee
Array Biopharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Array Biopharma Inc filed Critical Array Biopharma Inc
Publication of CO6751248A2 publication Critical patent/CO6751248A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CO13167580A 2010-12-13 2013-07-15 Compuestos sustituidos de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida como inhibidores de la tirosina quinasa receptora de tipo iii CO6751248A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42254710P 2010-12-13 2010-12-13

Publications (1)

Publication Number Publication Date
CO6751248A2 true CO6751248A2 (es) 2013-09-16

Family

ID=45478484

Family Applications (1)

Application Number Title Priority Date Filing Date
CO13167580A CO6751248A2 (es) 2010-12-13 2013-07-15 Compuestos sustituidos de n-(1h-indazol-4-il)imidazo[1,2-a]piridin-3-carboxamida como inhibidores de la tirosina quinasa receptora de tipo iii

Country Status (32)

Country Link
US (3) US9174981B2 (enExample)
EP (1) EP2651939B1 (enExample)
JP (3) JP5868996B2 (enExample)
KR (1) KR101974665B1 (enExample)
CN (3) CN103347882B (enExample)
AU (3) AU2011344001B2 (enExample)
BR (1) BR112013014854B1 (enExample)
CA (2) CA2821712C (enExample)
CL (1) CL2013001712A1 (enExample)
CO (1) CO6751248A2 (enExample)
CR (1) CR20130349A (enExample)
DK (1) DK2651939T3 (enExample)
ES (1) ES2540996T3 (enExample)
HR (1) HRP20150571T1 (enExample)
HU (1) HUE025416T2 (enExample)
IL (1) IL226911A (enExample)
ME (1) ME02172B (enExample)
MX (1) MX2013006763A (enExample)
MY (1) MY172110A (enExample)
NZ (1) NZ613235A (enExample)
PH (1) PH12013501221A1 (enExample)
PL (1) PL2651939T3 (enExample)
PT (1) PT2651939E (enExample)
RS (1) RS54070B1 (enExample)
RU (1) RU2591195C2 (enExample)
SG (1) SG191129A1 (enExample)
SI (1) SI2651939T1 (enExample)
SM (1) SMT201500165B (enExample)
TW (1) TWI527813B (enExample)
UA (1) UA112425C2 (enExample)
UY (1) UY33801A (enExample)
WO (1) WO2012082689A1 (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101779630B1 (ko) * 2009-12-21 2017-09-18 어레이 바이오파마 인크. cFMS 억제제로서 치환된 N-(1H-인다졸-4-일)이미다조[1,2-a]피리딘-3-카복사미드 화합물
RU2591195C2 (ru) * 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа
GB201315486D0 (en) * 2013-08-30 2013-10-16 Ucb Pharma Sa Antibodies
JO3517B1 (ar) 2014-01-17 2020-07-05 Novartis Ag ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
CN104496891A (zh) * 2014-12-06 2015-04-08 哈尔滨工业大学 吡啶衍生物2-叔丁氧基-6-亚甲基氯吡啶的合成方法
CN104974078A (zh) * 2015-06-25 2015-10-14 黄荣辉 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
EP3334717B1 (en) 2015-08-11 2020-07-01 Neomed Institute Aryl-substituted dihydroquinolinones, their preparation and their use as pharmaceuticals
WO2017024406A1 (en) 2015-08-11 2017-02-16 Neomed Institute N-substituted bicyclic lactams, their preparation and their use as pharmaceuticals
CA2994478C (en) 2015-08-12 2023-10-03 Neomed Institute Substituted benzimidazoles, their preparation and their use as pharmaceuticals
WO2017066876A1 (en) 2015-10-21 2017-04-27 Neomed Institute Substituted imidazopyridines, their preparation and their use as pharmaceuticals
EP3371172B1 (en) * 2015-11-02 2021-10-20 Genase Therapeutics B.V. Tetrahydroindazoles and medical uses thereof
CN105198799A (zh) * 2015-11-03 2015-12-30 江苏梦得电镀化学品有限公司 一种2-甲基-6-氯甲基吡啶盐酸盐的制备方法
WO2017127930A1 (en) 2016-01-28 2017-08-03 Neomed Institute Substituted [1,2,4]triazolo[4,3-a]pyridines, their preparation and their use as pharmaceuticals
AU2017283769B2 (en) 2016-06-14 2019-08-15 Novartis Ag Compounds and compositions for inhibiting the activity of SHP2
CN106187899B (zh) * 2016-06-28 2019-07-16 绍兴文理学院 一种氟代氮杂芳烃的合成方法
CN109790079B (zh) * 2016-07-29 2022-06-03 香港科技大学 有机锌试剂与杂环(拟)卤化物的C(sp3)-C(sp2)交叉偶联反应
WO2018083635A2 (en) 2016-11-04 2018-05-11 Auckland Uniservices Limited Tricyclic heterocyclic derivatives and uses thereof
MX385930B (es) * 2016-11-28 2025-03-18 Eisai R&D Man Co Ltd Sales de derivado de indazol y cristales de las mismas.
EP3624848A1 (en) 2017-05-19 2020-03-25 Syndax Pharmaceuticals, Inc. Combination therapies
IL271973B (en) 2017-07-28 2022-08-01 Yuhan Corp An improved process for the preparation of aminopyrimidine derivatives
WO2019178129A1 (en) 2018-03-13 2019-09-19 Shire Human Genetic Therapies, Inc. Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
CN111410654B (zh) * 2019-01-19 2022-05-17 江苏新元素医药科技有限公司 3-溴-5-(2-乙基咪唑并[1,2-a]吡啶-3-羰基)-2-羟基苯甲腈的合成
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
TWI759829B (zh) 2019-08-23 2022-04-01 財團法人生物技術開發中心 作為第iii型受體酪胺酸激酶抑制劑之雜環吡唑衍生物
US11370803B2 (en) 2019-09-18 2022-06-28 Takeda Pharmaceutical Company Limited Heteroaryl plasma kallikrein inhibitors
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
CA3164126A1 (en) 2019-12-09 2021-06-17 Syndax Pharmaceuticals, Inc. Antibodies for the treatment of chronic graft versus host disease
TW202542157A (zh) * 2024-01-04 2025-11-01 大陸商上海翰森生物醫藥科技有限公司 多環類衍生物抑制劑、其製備方法和應用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543523A (en) 1994-11-15 1996-08-06 Regents Of The University Of Minnesota Method and intermediates for the synthesis of korupensamines
CA2486187C (en) 2002-05-23 2013-02-19 Cytopia Pty Ltd. Kinase inhibitors
JP5442449B2 (ja) * 2006-12-22 2014-03-12 アステックス、セラピューティックス、リミテッド 新規化合物
NZ580327A (en) * 2007-04-03 2012-02-24 Array Biopharma Inc IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS
FR2925901B1 (fr) 2008-01-02 2011-03-04 Sanofi Aventis DERIVES DE N-HETEROCYCLIQUE-IMIDAZO°1,2-a!PYRIDINE-2- CARBOXAMIDES, LEUR PREPARATION ET LEUR APPLICATION EN THERAPEUTIQUE
EP2280705B1 (en) * 2008-06-05 2014-10-08 Glaxo Group Limited Novel compounds
TW201105669A (en) * 2009-07-30 2011-02-16 Irm Llc Compounds and compositions as Syk kinase inhibitors
KR101779630B1 (ko) * 2009-12-21 2017-09-18 어레이 바이오파마 인크. cFMS 억제제로서 치환된 N-(1H-인다졸-4-일)이미다조[1,2-a]피리딘-3-카복사미드 화합물
RU2591195C2 (ru) 2010-12-13 2016-07-10 Эррэй Биофарма Инк. Замещенные n-(1h-индазол-4-ил) имидазол [1,2-а]пиридин-3- карбоксамидные соединения в качестве ингибиторов рецепторной тирозинкиназы iii типа
JO3337B1 (ar) 2010-12-13 2019-03-13 Debiopharm Sa تركيبات صيدلية تشمل أليسبوريفير
CN102250246A (zh) * 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用

Also Published As

Publication number Publication date
IL226911A (en) 2016-09-29
TWI527813B (zh) 2016-04-01
PT2651939E (pt) 2015-08-04
RS54070B1 (sr) 2015-10-30
JP2013545808A (ja) 2013-12-26
HRP20150571T1 (xx) 2015-07-03
RU2013132758A (ru) 2015-01-20
CN103347882A (zh) 2013-10-09
CN109608449A (zh) 2019-04-12
CN103347882B (zh) 2016-05-11
AU2016222468B2 (en) 2017-12-21
JP5868996B2 (ja) 2016-02-24
PH12013501221A1 (en) 2022-03-30
AU2018201903A1 (en) 2018-04-12
UY33801A (es) 2013-06-28
HK1190709A1 (en) 2014-07-11
UA112425C2 (uk) 2016-09-12
JP2018065835A (ja) 2018-04-26
BR112013014854A2 (pt) 2016-10-18
EP2651939B1 (en) 2015-04-08
CN105924437B (zh) 2018-11-30
CN105924437A (zh) 2016-09-07
TW201305156A (zh) 2013-02-01
AU2018201903B2 (en) 2019-09-19
US9809590B2 (en) 2017-11-07
EP2651939A1 (en) 2013-10-23
RU2591195C2 (ru) 2016-07-10
KR101974665B1 (ko) 2019-05-02
CR20130349A (es) 2013-08-09
MY172110A (en) 2019-11-14
KR20140014109A (ko) 2014-02-05
AU2016222468A1 (en) 2016-09-22
BR112013014854B1 (pt) 2020-12-08
AU2011344001B2 (en) 2016-06-30
US20130274244A1 (en) 2013-10-17
CL2013001712A1 (es) 2013-12-06
ES2540996T3 (es) 2015-07-15
US10669269B2 (en) 2020-06-02
SG191129A1 (en) 2013-07-31
CA2821712C (en) 2019-02-12
CA3027814A1 (en) 2012-06-21
SI2651939T1 (sl) 2015-07-31
MX2013006763A (es) 2014-01-08
HUE025416T2 (en) 2016-02-29
CA2821712A1 (en) 2012-06-21
ME02172B (me) 2015-10-20
US20180086758A1 (en) 2018-03-29
WO2012082689A1 (en) 2012-06-21
US9174981B2 (en) 2015-11-03
PL2651939T3 (pl) 2015-10-30
NZ613235A (en) 2015-04-24
DK2651939T3 (en) 2015-06-01
JP2016040303A (ja) 2016-03-24
US20160002232A1 (en) 2016-01-07
SMT201500165B (it) 2015-09-07
BR112013014854A8 (pt) 2018-03-27

Similar Documents

Publication Publication Date Title
CR20120389A (es) COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4-IL)IMIDAZO[1,2-a] PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE cFMS
PH12013501221A1 (en) SUBSTITUTED N-(1H-INDAZOL-4-YL)IMIDAZO[1,2-a]PYRIDINE-3-CARBOXAMIDE COMPOUNDS AS TYPE III RECEPTOR TYROSINE KINASE INHIBITORS
JOP20200222A1 (ar) أشكال كريستالين لمثبط أنزيم كيناز تيروسين بروتون
EA201290894A1 (ru) Азетидиновые производные пиперидин-4-ила как ингибиторы jak1
CY1117745T1 (el) Ετεροκυκλικες ενωσεις και χρηση αυτων ως ρυθμιστες υποδοχεα τυπου iii κινασων τυροσινης
EA201171454A1 (ru) N-(ГЕТЕРО)АРИЛПИРРОЛИДИНОВЫЕ ПРОИЗВОДНЫЕ ПИРАЗОЛ-4-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ И ПИРРОЛ-3-ИЛПИРРОЛО[2,3-d]ПИРИМИДИНОВ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС-КИНАЗЫ
EA201401062A1 (ru) Бициклические пиразиноновые производные
EA201500628A1 (ru) Индолкарбоксамидные производные в качестве антагонистов p2xрецепторов
TR201821217T4 (tr) Tirozin kinaz aktivitesinin inhibisyonu için yeni kaynaşmış pirimidin türevleri.
EA201390766A1 (ru) БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ
EA201290940A1 (ru) Новые соединения как селективные антагонисты рецептора nk3, фармацевтическая композиция и методы их использования при нарушениях, опосредованных nk3 рецепторами
EA201290807A1 (ru) Циклобутановые и метилциклобутановые производные в качестве ингибиторов янус-киназы
EA201491607A1 (ru) Модуляторы толлподобных рецепторов
EA202090291A3 (ru) Производные бипиразола в качестве ингибиторов jak
EA201391239A1 (ru) Пирроло[2,3-d]пиримидиновые производные в качестве ингибиторов тропомиозин-связанных киназ
EA201591753A1 (ru) 3-пиримидин-4-илоксазолидин-2-оны в качестве ингибиторов мутантного idh
EA201490912A1 (ru) Производные [1,2,3]триазоло[4,5-d]пиримидина в качестве агонистов каннабиноидного рецептора 2
CR10682A (es) Compuestos de tiazol pirazolopirimidina
MX2012013206A (es) Inhibidores de quinasa biciclica fusionada.
AR080871A1 (es) Tieno[3,2-b]piridinas sustituidas como inhibidores de la actividad de la proteina tirosina quinasa
EA200970341A1 (ru) Пиразолиновые соединения в качестве антагонистов минералокортикоидных рецепторов
EA201400879A1 (ru) Производные тетрагидрохиназолинона в качестве ингибиторов tank и parp
DOP2010000317A (es) Nueva clase de espiro piperidinas para el tratamiento de enfermedades neurodegenerativas
MX2015002514A (es) Antagonistas de los receptores de quimiocina.
CY1116345T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΕΝΩΣΕΙΣ Ν-(1Η-ΙΝΔΑΖΟΛ-4-ΥΛ)ΙΜΙΔΑΖΟ[1,2-a]ΠΥΡΙΔΙΝΟ-3-ΚΑΡΒΟΞΑΜΙΔΙΟΥ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ ΤΥΡΟΣΙΝΗΣ ΥΠΟΔΟΧΕΑ ΤΥΠΟΥ III

Legal Events

Date Code Title Description
FG Application granted